Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas
- 111 Downloads
We have reported earlier a novel combination of four structurally designed synthetic neuropeptide analogs of vasoactive intestinal peptide (VIP), bombesin, substance P and somatostatin, code-named DRF 7295 which have anti-tumor efficacy for adenocarcinomas in vitro and in vivo (Jaggi et al., Invest New Drugs, 2008). The discovery, synthesis, in vitro and in vivo efficacy was reported (Jaggi et al., Invest New Drugs, 2008). Gastrointestinal tumor cells of the colon, pancreas and duodenum were found to most sensitive to DRF7295 in vitro and in vivo (Jaggi et al., Invest New Drugs, 2008). We have further investigated and report here the modulation of cellular signaling in gastrointestinal carcinomas by DRF 7295, which may be mediating its observed anticancer activity in these cancer types. DRF 7295 inhibits the binding of specific neuropeptides initiating a cascade of cellular signaling events leading to programmed cell death. It down regulates the second messenger cAMP, epidermal growth factor (EGF) dependent proliferation and the phosphorylated MAP Kinase pERK1/2 in gastrointestinal carcinomas, thus depriving the tumour cells of critical pro-proliferative cellular signals. It triggers bcl2 and Caspase 3 dependent apoptotic cell death and induces p53 tumor suppressor protein in the treated carcinoma cells in vitro. It has significant anti-angiogenic potential as reflected in the inhibition of tube like formation in the endothelial cells and down regulation of VEGF levels. Tumour xenograft studies confirmed the in vivo efficacy of DRF 7295 for gastrointestinal carcinomas (Jaggi et al., Invest New Drugs, 2008). The Phase I clinical trials have shown DRF 7295 to be well tolerated and devoid of systemic toxicities of the conventional cytotoxics (Mukherjee et al., Phase I dose escalating study of DRF7295: a new class of peptide based drugs. “Abstract” ASCO ID:948, 2003). The drug may have a promising role in disease stabilization in colorectal and other cancers. Thus DRF 7295 is a novel targeted drug in the class of signal transduction modulators, with potential for treatment of gastrointestinal carcinomas.
KeywordsNeuropeptide Gastrointestinal carcinomas Signaling Programmed cell death Targeted drug
This project was partly funded by Department of Science and Technology, Ministry of Science, Government of India.
We acknowledge the valuable inputs and the editing of the manuscript by Dr. Ritu Verma and Ms Alka Madaan post doc and research scientist respectively in the lab during the writing of the manuscript.
- 2.Jaggi M, Prasad S, Singh AT, Praveen R, Dutt S, Mathur A, Sharma R, Gupta N, Ahuja R, Mukherjee R, Burman AC (2008) Anticancer activity of a peptide combination in Gastrointestinal cancers targeting multiple neuropeptide receptors. Invest New Drugs. DOI 10.1007/s10637-008-9117-4
- 9.Pimentel E (1994) Growth factors and neoplasia. In: Handbook of growth factors: general basic aspects, vol. 1. CRC Press, USA, pp 329–337Google Scholar
- 16.Ostrowski J, Trzeciak L, Kolodziejski J, Bomsztyk K (1997) Increased constitutive activity of mitogen-activated protein kinase and renaturable 85 kDa kinase in human colorectal cancer. Br J Cancer 78:1301–1306Google Scholar
- 29.Mukherjee R, Jaggi M: Drug for treatment of cancer. US Patent 6,156,725Google Scholar
- 30.Mukherjee R, Jaggi M, Prasad S, Burman AC, Praveen R, Mathur A, Singh AT: Antiangogenic drugs. US Patent 6,492,330Google Scholar
- 31.Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT, Mathur A: Somatostatin analogs for the treatment of cancer. US Patent 6,316,414Google Scholar
- 32.Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT, Sharma R: Peptides for the treatment of cancer. US Patent 6,828,304Google Scholar
- 33.Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT: Substance P analogs for the treatment of cancer. US Patent 6,596,692Google Scholar
- 35.Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M (2005) Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF and receptors of the EGF/HER family in PC-3 and DU 145 human androgen independent prostate cancers. Prostate 64:303–315PubMedCrossRefGoogle Scholar
- 36.Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, Hines OJ, Strieter R, Rozengurt E (2005) Broad spectrum G protein coupled receptor antagonist (d-Arg, d-Trp 5,7, 9, Leu 11) SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65:2738–2745PubMedCrossRefGoogle Scholar
- 43.Tallet A, Chilvers ER, Hannah S, Dransfield I, Lawson MF, Haslett C, Sethi T (1996) Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. Cancer Res 56:4255–4263Google Scholar
- 44.Mukherjee R, Doval D C, Raghunadharao D, Majumdar A, Ganguly S, Jaggi M, Prasad S, Singh AT, Burman AC (2003) Phase I dose escalating study of DRF7295: A new class of peptide based drugs. “Abstract” ASCO ID:948Google Scholar